GCLM and coronary artery disorder: PBMCs from coronary artery disease (CMD) patients with CKD expressed increased amounts of the enzyme GCLM (glutamate cysteine ligase modifier) [73], which was congruent with our finding of increased glutamate metabolism in the DM_CKD animals.